Del Laboratories: Following the acquisition of Del by DLI Holding Corp. later this year, Dan K. Wassong will retire. William McMenemy, currently executive vice president of marketing at Del will become president and chief executive officer. Charles J. Hinkaty, vice president of Del and president of Del Pharmaceuticals, will become chief operating officer. Harvey Alstodt, currently executive vice president of sales, will become president of global business. Enzo J. Vialardi will remain executive vice president and chief financial officer of Del.